ABSTRACT
INTRODUCTION
Retroviruses have been used as an important tool in developing gene therapy vectors. Their ability to stably integrate genetic information into the host genome has enabled the exploitation of these viruses for many gene delivery applications. Gammaretroviral vectors have been used successfully to rectify defects of SCID-X1 and other diseases (1) . However, despite the efficiency in gene delivery, insertional mutagenesis can result in clonal expansion of cells bearing specific integrants (2) , associated with the preferential integration of murine leukemia virus (MLV) vectors upstream of transcription start sites (TSS) and CpG islands near promoter regions (3) . This complicates their use in gene therapy.
In the retroviral replication cycle, the viral reverse transcriptase enzyme converts the single-stranded RNA viral genome into double-stranded DNA, which is associated within a preintegration complex (PIC). MLV requires cells to undergo mitosis. The viral p12 protein, which is part of the PIC, is responsible for tethering the viral genome to the host mitotic chromatin (4) (5) . However, the p12 protein does not mediate targeting of the viral PIC toward genomic hotspots for retroviral integration such as TSS and CpG islands (5) . The viral integrase (IN), upon entry into the host nucleus, mediates the integration of the viral DNA into the host genome (6) . The viral IN protein is the primary viral determinant for target-site selection (7) .
It has recently been shown that the host bromo and extraterminal (BET) domain proteins Brd 2, 3 and 4 bind the viral IN protein through their conserved ET domain (8) (9) (10) . The down regulation of BET proteins with siRNAs (8) (9) as well as treatment with a small molecule inhibitor JQ1, which selectively impairs BET protein association with chromatin, showed decrease in preferential integration targeting at TSS and CpG islands (8) (9) (10) . In the presence of LEDGF-BET protein chimeras (10) , integration can be shifted toward LEDGF binding sites. In vitro interaction studies and coimmunoprecipitation of overexpressed MLV IN in mammalian cells have mapped the BET binding sites to different domains of MLV IN including the catalytic core domain (CCD) (9) , the C-terminal domain (CTD) (8, 10) and the IN C-terminus (10) .
In this report, we demonstrate that the C-terminal polypeptide segment of the viral IN protein, which we refer to as the tail peptide (TP), is a key determinant in mediating the interaction of the viral IN protein with the ET domain of the BET proteins. This interaction provides a structural basis for global in vivo integration-site preferences. MLV virus bearing IN lacking this C-terminal 28-residue TP are viable in tissue culture (11) (12) and in vitro (13) (14) . Hence, deletion of the TP does not disrupt the catalytic properties of IN. MLV IN lacking the TP lose their interaction with BET proteins, thus presenting a direct mechanism to alter target-site utilization. Virus bearing IN lacking the TP, or with it replaced with other peptides, exhibits markedly diminished viral integrations in mammalian cells near TSS, CpG islands, and known BET binding sites. 
MATERIAL AND METHODS

Plasmid constructs
Protein purification for NMR studies
Protein expression and purification from the pET-based construct for MLV IN CTD was performed as previously described (15) (16) (17) (18) with the following modifications: protein expression was induced with 1 mM IPTG at 17
• C for 25 h. Induction was carried out in MJ9 media (17) (18) in the presence of either 15 N-labeled ammonium chloride or 15 N ammonium chloride plus uniformly 13 C-enriched glucose. Following Ni-NTA resin purification (Qiagen) as per manufacturer's instructions, fractions eluted in 400 mM imidazole were pooled and concentrated to a volume of less than 250 L using an Amicon Ultracel-3K centrifugal filter unit (Millipore). The concentrated protein fraction was then injected into an AKTA FPLC and resolved on a Superdex 75 gel filtration column (GE Healthcare) in 20 mM sodium phosphate pH 8.0, 300 mM NaCl, 50 mM potassium glutamate (KC 5 H 8 NO 4 ) and 5 mM 2-mercaptoethanol. The eluted fractions were then pooled and concentrated using an Amicon Ultracel-3K centrifugal filter unit (Millipore). All isotopes were purchased from Cambridge Isotopes Laboratories.
Next generation sequencing of MLV IN C-terminal truncations
Sequencing was performed exactly as described before (5) . Analysis of integration sites near Brd2, 3 and 4 binding sites were correlated using ChIP-seq data (19) and analyzed as described previously (8) . The statistical test rely on the variance-covariance matrix of the relative ranks of the integration sites to construct Wald-type test statistics and referred to the Chi Square distribution to obtain P values (20) . Datasets used in the analysis: the inset box defines the data sets used in the analysis; FV fibroblast (21), HIV-1 (22) , MLV ( (5) Table S4 ).
NMR analysis of MLV CTD structure and ET interactions
Single-( 15 N) and double-( 13 C, 15 N) enriched MLV IN CTD protein samples for studies of complex formation were concentrated to approximately 200 M-1 mM concentration and where indicated, mixed with 2 mM unlabeled Brd3 ET in a buffer containing 5% 2 H 2 O, 50 mM DSS, 300 mM NaCl, 50 mM potassium glutamate, 25 mM sodium phosphate at pH 7.0 or pH 8.0 and 5 mM 2-mercaptoethanol. Samples for NMR studies at pH 6.5 were prepared as described for pH 8.0, except at 100 mM NaCl and in the absence of 2-mercaptoethanol. Sequence-specific backbone 1 H, 13 C and 15 N resonance assignments for free and ETbound IN 329-408 were determined at pH 7.0 and 8.0 using standard triple NMR resonance experiments (23) . Resonance assignments and the solution NMR structure determination of IN 329-408 at pH 6.5 are reported elsewhere (PDB ID: 2M9U, BMRB ID: 19299). All spectra were recorded using a Bruker Avance 800 MHz spectrometer at 25
• C. NMR data were processed using NMRPipe (24) and SPARKY (T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, San Francisco). The oligomeric states of both free and complexed proteins (1:1 molar ratio of IN CTD:Brd3 ET at 100 M or 200 M) were assessed by measurements of rotational correlation times computed from 15 N T 1 and T 2 nuclear relaxation measurements, as described previously (25) (26) . Detailed protocols and calibration data for molecular correlation time measurements based on 15 N nuclear relaxation rate data are provided online at (http://www.nmr2.buffalo.edu/nesg.wiki/ Main Page). Peptides used for the TP competition assay are 'WT TP'--SRLTWRVQRSQNPLKIRLTREAP; and 'mutant TP'--SRLTARVQRSQNAAAIALTREAP (Pep-tide 2.0 Inc.). The peptides were solubilized in deionized water to a final concentration of about 3 mM.
In vitro pull down assays
Pull-down assays were performed as described (8) .
Protein interaction trap assay
The protein interaction trap assay (27) was adapted and performed as described in Supplementary Data.
Data deposition
The sequences reported in this paper have been deposited in the National Center for Biotechnology Information Sequence Read Archive (project accession number SRP021184).
RESULTS
The structure of the MLV IN CTD changes in the presence of the Brd3 ET domain
The MLV IN interacts through its CTD with the BET family members through the ET domain (8) . We have determined the three-dimensional structure of the MLV IN CTD (28) (PDB ID 2M9U) using conventional triple-resonance solution-state NMR methods. It consists of an SH3 fold followed by a long unstructured tail ( Figure 1A, B Supplementary Table  S1 .
In transitioning from pH 6.5 to pH 8.0, the HSQC spectra of the free CTD domain exhibit attenuation of surface amide proton intensities due to base-catalyzed amide proton exchange. This attenuation of amide proton intensities is illustrated in Supplementary Figure S1A and B. However, in the spectra of the complex formed between 15 N-enriched IN CTD and unlabeled Brd3 ET domains, many of these same amide sites do not exhibit attenuation due to solventexchange broadening. This is because they are occluded due to structure formation in the TP region and/or due to the interface formed with the ET domain. (1 mM) and Brd3 ET (2 mM) was 1:2 at the concentrations indicated. Backbone amide resonances that are not affected by complex formation are labeled with sequence-specific assignments in black; assigned amide resonances that are not observable due to solvent-exchange broadening in the absence of ET, but become observable upon complex formation, as well as resonances exhibiting significant CSPs upon complex formation are labeled in magenta. All amide peak resonances not observable due to solvent-exchange broadening in the absence of ET, but become observable upon complex formation are marked with black circles; some of these could not be unambiguously assigned at pH 8.0. The curved green arrows indicate the CSPs due to complex formation of the amide resonances assigned to residues L399, L403, A407 and the side-chain indole NH⑀ resonance of W390. Tryptophan W347 and W369 NH⑀ side chain indole resonances with significant proton exchange rate reduction due to complex formation are also indicated. Peak resonances labeled in green are assigned to the non-cleavable affinity tag. 
The absence of the IN CTD TP disrupts the heterodimeric interaction
Having established that the heterodimeric IN CTD-Brd3 ET interaction is facilitated primarily by residues in the TP that are largely disordered in the IN free CTD (28), we next explored the impact of truncating these disordered residues on complex formation. Molecular rotational correlation time ( c ) measurements, based on simple 1D 15 N nuclear relaxation rate measurements, can be used to estimate molecular mass changes upon complex formation under precisely defined conditions (25) . These data are summarized in Figure 2A with supporting data in Supplementary Figure S2 . A calibrated plot of c versus molecular weight (Figure 2A ) indicates that at 100 M concentration, 300 mM NaCl, pH 8.0 and 25
• C, MLV CTD construct IN 329-408 behaves as a monomer ( c = 6.6 ns, MW ∼ 10.5 kDa). Addition of stoichiometric amounts of unlabeled Brd3 ET results in a heterodimer ( c = 10.9 ns, MW ∼ 18 kDa). Two MLV IN CTD constructs truncated at the Cterminus ( C), IN 329-385 and IN 329-385 XN were also found to behave as monomers in either the presence or absence of unlabeled Brd3 ET (i.e., c = 4.5 -6.1 ns, MW ∼ 8 ± 1 kDa), as illustrated in Figure 2A . Figure S3) . These data demonstrate that truncation of the C-terminal disordered TP region does not affect the 3D structure of the rest of the CTD domain, including the core SH3 fold. The activity of IN constructs truncated at residue 385 has been extensively characterized in vitro and in vivo (11) (12) (13) (14) (29) (30) . Additional characterization with respect to viral titer, reverse transcriptase activity, minus-strand strong stop and plus-strand extension, Alu-PCR and two-end integration assays are described in the Supplementary Data.
These NMR studies of the IN CTD in the presence of the Brd3 ET domain provide biophysical evidence of the two proteins interacting, with changes in the MLV IN CTD NMR spectra clustering within the disordered IN Cterminal TP. The interaction with the Brd3 ET domain requires the C-terminal polypeptide region, and is suppressed by deletion of residues 386-408.
Additional protein interaction studies corroborate the role of the TP region in the structural basis of Brd3 ET binding. Figure 2B and Supplementary Figure S4 Table 1 ). Negative controls remained white, other than a very weak background interaction observed between the MLV IN expression construct (pGADNOT-5'mIN) and the empty vector (pSH2-1). Proteins expressing the HIV-1 p66 and p51 reverse transcriptase subunits (pSH2-p66 and pGADNOT-p51) served as positive controls.
Taken together, the protein interaction data summarized in Figure 2 , Table 1 and Supplementary Figures S3 and S4 unequivocally demonstrate that the TP region of MLV IN, including residues 386-408, is critical for interactions with the ET domains of Brd2, Brd3 and Brd4 BET family members.
TP competition assay shows sequence-dependent disruption of the heterodimeric interaction
The importance of the TP region was further validated using a 24 amino-acid peptide (WT TP; Figure 3A ) in a competition assay to disrupt the MLV IN CTD and Brd3 ET complex. The TP region contains a 390 WX 7 PLK I / L R 402 Figure S1C) . Accordingly, in addition to the wild-type (WT) peptide, a second 24-residue mutant TP in which all five of the conserved amino acids in the consensus motif are replaced with alanine ( Figure 3A ) was also studied. Rotational time ( c ) measurements, summarized in Supplementary Table S2 and supported by data in Supplementary Figure S5 , demonstrate that the 24-residue WT TP disrupts the heterodimeric IN CTD-Brd3 ET complex. [ 15 N-1 H]-HSQC spectra presented in Figure 3B further demonstrate that the WT TP disrupts the complex formed between 15 Figure 3B . The mutant TP, replacing five key residues with alanine, does not disrupt the complex between IN CTD (construct IN 329-408 ) and Brd3 ET ( Figure 3C ), that is, the spectrum of the complex is not altered by adding the mutant TP peptide. These data demonstrate the importance of some or all of these five residues in the energetics of complex formation.
Truncation of the CTD C-terminal TP results in decreased integration at TSS and CpG islands.
A hallmark of MLV integration is the preferential integration within 2 kb of TSS and CpG islands ( Figure 4A Figure S4 and Table 1 ). Mapping the integration site profile for MLV lacking the IN Cterminal TP thus tests whether the binding of BET family proteins drives MLV integration to TSS and CpG islands and presents a direct mechanism to alter the MLV integration preference.
Viruses lacking the C-terminal TP ( C) are viable in tissue culture and multiple tags have been inserted into the Cterminal segment of MLV IN (11,12,30-31) . The integration target-site distribution of three constructs lacking the C-terminal 23 amino acids of IN were examined (IN 1-385 XN (in6215a) (11) Table S4 ). For example, integration of IN C constructs plus or minus 1 kb of TSS averaged ∼2.5% of the total integrants, whereas ∼12% of the WT MLV mapped within this interval. Levels of the MLV IN C constructs remained above the published levels for the Foamy virus and HIV-1 integrants in 293 and 293T (Figure 4 and Supplementary Table S4 ). Loss of localization to TSS and CpG islands was not specific for oncogenes; analysis of housekeeping genes showed a similar decrease in targeting their promoter regions (Supplementary Figure S7) . Analysis of the local sequence bias at the site of the target DNA duplication revealed that the IN C constructs maintained the characteristic palindromic consensus sequence of MLV (Supplementary Figure S8) at the scissile bonds (32) . These results indicate that the loss of the IN C-terminal TP, which is the key IN:BET interaction domain, results in redistribution of viral integration sites away from promoter regions without grossly altering virus viability (11) .
MLV IN C integration sites lose association with known BET protein binding sites in 293 cells
In 293 cells, binding sites of BET proteins (Brd2, Brd3 and Brd4) have been identified by chromatin immunoprecipita- ET (200 M) was 1:1 and the mutant peptide was added at 3-fold excess (600 M). The mutant TP does not disrupt the complex, and the spectrum is not changed when the peptide is added. In both panels, backbone amide resonances are labeled in black and peak resonances labeled in magenta are assigned to the non-cleavable affinity tag. Buffer conditions are as follows--buffer 1: 25 mM sodium phosphate pH 8.0, 300 mM NaCl, 50 mM potassium glutamate, 5 mM 2-mercaptoethanol. Buffer 2: 25 mM sodium phosphate pH 8.0, 360 mM NaCl, 60 mM potassium glutamate, 6 mM 2-mercaptoethanol. tion and mapped onto the human genome (19) . The correlation of these BET protein binding sites and integration sites of MLV WT IN and IN C viruses was examined ( Figure  4C ). Analysis was performed using the total BET protein binding sites ( Figure 4C : promoters + within genes + intergenic regions) and as well as those limited to specific promoter regions ( Figure 4D ). WT IN integrations correlated with identified Brd2, Brd3 and Brd4 binding sites compared to matched random controls throughout the host chromosomes. Integrants obtained from all three IN C isolates showed a marked decrease (∼2-fold, P < 0.001) compared to the WT IN integrants. Interestingly, this effect was localized to within 100 bp of a known BET protein-binding site. Approximately 9-13% of BET protein binding sites map within 2 kb of genes (19) . Analysis of the MLV integrants from IN C isolates indicated a more pronounced decrease in association with BET protein binding sites (4-fold) located within promoters upon loss of the IN C-terminal TP ( Figure 4D) , mapping to within 100 bp of the identified Brd2, Brd3 or Brd4 sites. These results indicate that the loss of the IN C-terminal tail results in the loss of targeting to identified binding sites of BET proteins.
DISCUSSION
The results of this study establish the molecular mechanism of MLV retroviral integration into TSS and CpG islands by tethering MLV IN with BET family proteins Brd2, Brd3 and Brd4 ( Figure 5 ). Using solution NMR and biochemical studies, the interaction was localized predominantly to the C-terminal polypeptide tail segment of the MLV IN protein, including residues 386-408. In the absence of the BET proteins, the MLV IN C-terminal peptide (TP) is unstructured. It becomes structured upon complex formation with the Brd3 ET domain. This disorder-to-order transition may contribute a significant entropic component to the energetics of complex formation. The TP is non-essential for virus viability; however, viruses lacking the TP show marked diminution of integrations at the TSS and CpG islands, which are favored targets of MLV DNA integration in chromosomes. Loss of the MLV IN TP also correlated with the loss of association with BET protein binding sites within 293 cells.
Backbone CSPs upon complex formation indicate a change in the environment of the corresponding backbone atoms. Such changes implicate the corresponding region of the polypeptide or protein in the molecular recognition process, but do not necessarily demonstrate a direct contact of the corresponding residue in the intermolecular interface; that is, CSPs do not necessarily indicate direct intermolecular interactions. Site directed mutations could be used to validate the role of specific atoms in interfacial interactions, but the interpretation of such data requires structural data demonstrating that such sequence changes do not disrupt the structure of the CTD or the CTD-ET complex distal from the site of mutation. In any case, the extensive CSP data for free and ET-bound IN CTD, summarized in Figure 1 and Supplementary Table S1 , provide unequivocal evidence for structural changes in C-terminal TP region of IN CTD upon complex formation, providing a structural basis for the interaction between these two domains. Figure S1C) . This homology ex- tended to the core consensus of 390 WX 7 PLKJR 402 ( Figure  S1C ; J = I/L) in RaLV, GaLV and KoRV, but the integration site preferences for these viruses have not been analyzed. It is predicted that these would be critical for the interaction with BET family members. Indeed, the peptide competition assay (Figure 3 and Supplementary Table S2) shows that one or more of residues W390, P398, L399, K400 and R402 contribute to the energetics of complex formation. Additionally, IN W390A has been shown to have reduced binding affinity for Brd4 ET (10) .
The function of the IN C-terminal tail appears analogous to that of the histone (34) (35) and RNA polymerase II tails (36) , as an otherwise unstructured docking site for additional proteins or regulatory factors ( Figure 5 ). Interestingly, the NS1 protein of influenza A H3N2 subtype is proposed to use a related histone mimic as a means to associate with the human PAF1 transcription elongation complex and thus inhibit the antiviral response (37) .
Targeting of IN integration to active promoter regions is beneficial for expression of the viral genome for subsequent rounds of infection. However, targeting to promoter regions only accounts for approximately 25% of all MLV retroviral integrations. Loss of targeting through the BET proteins does not affect the majority of MLV integration events. The local sequence selection at the site of integration (LOGOs analysis) remain unchanged in the absence of the IN TP. The quantitation of integration copy numbers of the three replicating IN C isolates was statistically similar to WT IN and consistent with the 2-fold variation observed for a single round of infection (12) . Additionally, reverse transcription of the viral genome into dsDNA is not grossly affected by the absence of the IN TP (Supplementary Figure  S6B and C). Variations in viral titers (between 2-and 4-fold) and the time course of viral spread were observed between the three IN C isolates. These assays depend on the level of expression of the viral or transgene mRNA. Loss of targeting to highly expressed promoter regions can result in a decrease in the total level of viral mRNA produced and thus be reflected in minor variations in viral titer and subsequent proviral integrations. Alternatively, the differences in the IN terminal amino acids may affect the association with other unidentified host factors.
Recently, it was reported that three residues in the MLV IN CCD are important in the interaction with BET proteins (9) . It is unclear whether these mutations compromise MLV IN catalytic activities or indirectly affect interactions with BET proteins. Despite an intact TP region, interaction with BET proteins was lost in the context of these CCD mutations. It is possible that the presence of a C-terminal FLAG tag used in that study might compromise the binding potential of the TP region. Loss of the IN TP though did not compromise IN catalytic activities within the CCD or those requiring multimerization including two-end concerted integration (Supplementary Figure S9) .
Interestingly, BET family members have been implicated in other viral systems and used to regulate viral transcription as well as tethering the viral DNA complexes to mitotic chromosomes. Both the KSHV LANA protein and the Merkel cell polyomavirus T antigen bind Brd4 through protein-protein interactions with the ET domain (38) (39) (40) . In addition, various animal and human papilloma viruses interact with the host protein Brd4 (41) . For MLV, integration at BET protein binding sites positions the virus within transcriptionally active regions of the host chromosomes and should facilitate viral gene expression.
Multiple retroviral and retrotransposon systems utilize host proteins to influence their position of viral integration. Integration of HIV-1 is directed within genes through asso-ciation with the host factor LEDGF/p75 (22, (42) (43) (44) . Yeast Ty1 and Ty3 target integration into tRNA genes. Ty3 interacts with Brf1, TFIIB and TBP, which are involved in Pol III transcription (45) . Recent studies of Ty1 targeting to tRNA genes implicate a possible histone modification near Pol III transcription sites as a driving factor for recognition (46) . For Tf1, it is known that a chromodomain at the C-terminus interacts with the host Atf1 protein to drive integration into genes associated with environmental stresses (47) .
The function of the ET domain of BET family members is not well defined. Recent studies have identified NSD3, JMJD6, CHD4, GLTSCR1 and ATAD5 proteins as binding partners to the BET family members ET domain (48) and thus the ET domain functions to recruit specific effector proteins to regulate transcriptional activity. It is not known if binding of the MLV IN TP interferes with the function of the ET domain and/or the association of cellular proteins to this domain. The solution structure of the Brd4 ET domain consists of three ␣-helices plus a loop structure, with no close structural homologs (49) . Binding to IN is localized to the acidic patch in the ␣2-␣3 loop region (9-10). The solution structure of the ET domain:IN CTD complex will be interesting to elucidate.
Mapping of WT integrated MLV proviruses shows favored targeting within 2 kb of the TSS and CpG islands (3) . For the WT IN, correlation with the chromatin binding sites of BET proteins showed a tighter association, favoring integration within 100 bp of the defined BET protein binding sites for Brd2, 3 and 4. The two analyses measure distinct features, as the positions of the BET sites with respect to the TSS are not defined. Loss of the IN TP did not affect a panel of additional features, including integration in gene dense regions (50) . MLV integrants are reported to be associated with the supermarkers (51) containing H3K4me1, H3K4me3, H3K9ac chromatin marks and STAT1 binding sites. Indeed, comparison of the integration sites of the WT IN versus the IN C constructs from this study with the epigenetic maps of HeLa and resting T cells correlated the loss of the IN TP with the loss of integrants at H3K4me1, H3K4me3, H3K9ac chromatin marks, STAT1 binding sites and H2AZ sites (data not shown). Understanding the additional proteins that assemble with the preintegration:BET complexes will shed light on the molecular mechanisms associated with recognizing these supermarkers as well as those that stabilize gene or promoter-specific targets. This knowledge has direct implications for understanding the potential of murine-based vectors for gene activation resulting from insertional viral mutagenesis.
Eliminating the interactions with BET family members has implications for the use of gammaretroviral vectors for gene therapy and gene delivery. Foamy viruses, which have limited bias to integrate at TSS and CpG islands have been shown to be apathogenic in humans (52) . Vectors lacking the IN TP would decrease targeting to promoter regions of all classes of genes, not specifically oncogenes. This nonetheless has the potential to decrease the probability of promoter/enhancer insertional mutagenesis due to viral integration at promoter regions. The modulation of overall expression of the transgene due to chromosomal positional effects might become more evident in the absence of BET protein targeting. Current studies are aimed at defining the potential of oncogene activation resulting from integration of MLV bearing the IN C proteins.
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